Angiotensin ii type 1 receptor inhibitors, blood pressure lowering agents, as well as agents for preventing and / or improving hypertension
Propolis from Hawaii, USA, Taiwan, or genus Macaranga plants are used to develop angiotensin II type 1 receptor inhibitors for effective antihypertensive and anti-arteriosclerotic treatments, addressing regional composition variability and safety concerns.
Patent Information
- Application Number
- JP2023084001
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-22
- Publication Date
- 2024-12-04
- Estimated Expiration
- 2043-05-22
AI Technical Summary
Existing angiotensin II type 1 receptor inhibitors derived from specific propolis sources do not effectively address hypertension, and their efficacy varies due to regional differences in propolis composition.
Utilizing propolis produced in Hawaii, USA, Taiwan, or derived from the genus Macaranga plants, which exhibit superior angiotensin II type 1 receptor inhibitory effects, as active ingredients in antihypertensive agents.
These propolis sources provide effective angiotensin II type 1 receptor inhibition, leading to potential antihypertensive and anti-arteriosclerotic effects, suitable for use in foods, drinks, and pharmaceuticals as safe and sustainable treatments.
Smart Images

Figure 2024167733000001
Abstract
Description
[Technical field]
[0001] The present invention relates to an angiotensin II type 1 receptor inhibitor, an antihypertensive agent, and an agent for preventing and / or improving hypertension, and more specifically, to an angiotensin II type 1 receptor inhibitor, an antihypertensive agent, and an agent for preventing and / or improving hypertension, which contains propolis. [Background technology]
[0002] The number of hypertension patients in Japan is approximately 10 million (2017), the annual medical expenses are approximately 1.8 trillion yen (2017), and the number of deaths due to hypertension is approximately 9,600 (2017). Therefore, there is a demand for foods, beverages, and medicines that have a safe blood pressure lowering effect and are useful for the prevention and treatment of hypertension.
[0003] The renin-angiotensin system is involved in homeostatic regulation of systemic blood pressure, body water volume, and electrolyte balance. Angiotensin II is a peptide with a strong hypertensive effect, and it is known that angiotensin II exerts its effect via the angiotensin II receptor on the cell membrane.
[0004] Angiotensin II receptor (ATR) is a G protein-coupled receptor that plays an important role in regulating blood pressure. There are two types of ATR receptors: type 1 receptor (hereinafter sometimes referred to as "AT1"), which increases blood pressure, and type 2 receptor (AT2), which decreases blood pressure. Blood pressure is regulated by the cooperation of these two types of receptors, and this cooperation is controlled by the bioactive peptide angiotensin II, and whether blood pressure increases or decreases depends on which receptor angiotensin II binds to. Therefore, angiotensin II is a target for the treatment of hypertension, and angiotensin receptor antagonists, which inhibit its binding, are widely used as a treatment for hypertension. Hypertension, also known as a lifestyle-related disease, is also a major risk factor for life-threatening diseases such as cerebral infarction, myocardial infarction, and arteriosclerosis (https: / / www.kyoto-u.ac.jp / sites / default / files / embed / jaresearchresearch_results2018documents180702_201.pdf).
[0005] Propolis is a glue-like substance made by mixing tree sap, plant buds and exudates collected by honeybees with beeswax and other substances, and is known to have antibacterial, antioxidant, anti-inflammatory, antitumor and anti-allergic effects.
[0006] Since the components of propolis are influenced by the type and composition of the original plant from which it is made, it is known that the types and amounts of active ingredients contained in propolis, as well as their physiological activities, vary greatly depending on the country or region where it is harvested.
[0007] In recent years, research into the components of propolis from different origins has been progressing. For example, the main components of Brazilian propolis, which is derived from Baccharis doracunclifolia, are p-coumaric acid, artepillin C, drupanin, baccharin, and other cinnamic acid derivatives. On the other hand, the main components of Chinese, European, and Australian propolis, which is derived from poplar, are flavonoids such as chrysin and galangin.
[0008] Patent Document 1 reports an angiotensin II receptor antagonistic composition containing propolis, which contains quercetin, p-coumaric acid, and artepillin C, and further contains chrysin, galangin, or caffeic acid phenethyl ester. Propolis origins include Brazilian propolis, Chinese propolis, Australian propolis, Uruguay propolis, and Japanese propolis, and a preferred propolis is a mixture of Brazilian and Chinese propolis. Quercetin derivatives, p-coumaric acid, and artepillin C are mainly contained in Brazilian propolis, while chrysin, galangin, and caffeic acid phenethyl ester are contained in Chinese propolis and Uruguay propolis. Therefore, these propolis are known to contain a large amount of polyphenols. [Prior art documents] [Patent documents]
[0009] [Patent Document 1] JP 2004-161664 A Summary of the Invention [Problem to be solved by the invention]
[0010] The present invention aims to provide a novel angiotensin II type 1 receptor inhibitor, as well as an agent for lowering blood pressure and an agent for preventing and / or ameliorating hypertension. [Means for solving the problem]
[0011] Since propolis is made from plants harvested by bees, the ingredients vary depending on the place of origin, and it is expected that the effect will vary depending on the place of origin. Therefore, the present inventors have conducted extensive research to achieve the above-mentioned object, and have found that propolis from Hawaii, USA, and Taiwan, which are derived from different original plants, as well as propolis derived from Macaranga genus plants, have better angiotensin II type 1 receptor inhibitory effect than propolis from Brazil, thus completing the present invention.
[0012] That is, the present invention relates to the following [1] to [7]. [1] Angiotensin II type 1 receptor inhibitor containing propolis from Hawaii, USA and / or propolis from Taiwan. [2] Angiotensin II type 1 receptor inhibitors, including propolis derived from plants in the Macaranga genus. [3] An antihypertensive agent comprising the angiotensin II type 1 receptor inhibitor described in [1]. [4] An antihypertensive agent comprising the angiotensin II type 1 receptor inhibitor described in [2]. [5] An agent for preventing and / or ameliorating hypertension, comprising the angiotensin II type 1 receptor inhibitor described in [1]. [6] An agent for preventing and / or improving hypertension, comprising the angiotensin II type 1 receptor inhibitor described in [2]. [7] The agent according to any one of [1] to [6], which is a food or beverage, a medicine, or a quasi-drug. Effect of the Invention
[0013] Propolis from Hawaii, USA, and Taiwan, as well as propolis derived from plants of the Macaranga genus, have excellent angiotensin II type 1 receptor inhibitory activity, and are therefore useful as active ingredients in angiotensin II type 1 receptor inhibitors, blood pressure lowering agents, and agents for preventing and / or improving hypertension.
[0014] Moreover, since propolis has traditionally been used as a food ingredient, it is highly safe. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0015] Hereinafter, the embodiment for carrying out the present invention will be described in detail, however, the present invention is not limited to the following embodiment.
[0016] In this specification, the term "comprise" includes the meanings of "essentially consist of" and "consist only of."
[0017] In addition, in this specification, "angiotensin" means angiotensin.
[0018] In this specification, the "angiotensin II type 1 receptor inhibitory effect" refers to the effect of antagonizing angiotensin II and inhibiting the binding of angiotensin II to angiotensin II type 1 receptor, and is also called angiotensin II type 1 receptor antagonistic effect.The angiotensin II type 1 receptor inhibitory effect can be evaluated according to a known method, for example, by using cells expressing angiotensin II type 1 receptor, measuring the amount of angiotensin II binding when angiotensin II is added, and comparing the measured values when the sample is present and when it is not present.
[0019] The angiotensin II type 1 receptor inhibitor of the present invention contains propolis produced in Hawaii, USA and / or propolis produced in Taiwan as an active ingredient.
[0020] In another embodiment, the angiotensin II type 1 receptor inhibitor of the present invention contains propolis derived from a plant of the genus Macaranga as an active ingredient.
[0021] Propolis is a resinous or waxy substance that constitutes the walls of beehives, and is made by mixing plant shoots or resins collected by bees with the saliva of bees. Propolis can be obtained, for example, as a beekeeping product in a conventional manner. In one embodiment of the present invention, propolis produced in Hawaii, USA and Taiwan is used. In addition to Hawaii, USA and Taiwan, propolis produced in other places such as China, European countries, Russia, Oceania, and America may be used in combination. Propolis can be used alone or in combination of two or more different places.
[0022] The propolis used in one embodiment of the present invention is not particularly limited as long as it is collected in Hawaii, USA or Taiwan. Among them, propolis from Hawaii, USA and Taiwan is preferably derived from a plant of the genus Macaranga.
[0023] In another embodiment of the present invention, the propolis is propolis derived from a plant of the Macaranga genus.
[0024] The propolis used in another embodiment of the present invention is not particularly limited as long as it is derived from the above-mentioned plants, and may be derived from any place of origin, such as Taiwan, European countries, Russia, Oceania, America, etc., and among them, propolis from Hawaii, USA and propolis from Taiwan are preferred.
[0025] The propolis in the present invention may be, for example, a propolis lump, or a processed propolis product obtained by subjecting a propolis lump to some kind of processing. The processed propolis may be, for example, a propolis lump that has been subjected to processing such as pulverization, extraction, extract concentration or powderization, powder granulation, or the like, or may be an extraction residue remaining after extraction. That is, the processed propolis may be, for example, a pulverized propolis, an extract, a concentrated extract, an extract powder, an extract granule, an extraction residue, or the like. The extraction may be, for example, water extraction, hydrophilic organic solvent extraction, supercritical extraction, or the like. Examples of hydrophilic organic solvents include ethanol, glycerin, and 1,3-butylene glycol. The propolis extract may be obtained by extraction from a propolis lump, or may be obtained by further extraction from the residue after extraction. In addition, the extraction solvent may be used alone, or two or more types may be used in any combination as a mixed solvent. The processing method may be one, or two or more may be combined. As the processed propolis, a propolis hydrophilic organic solvent extract is preferable because it is a product in which the effective components of propolis are extracted efficiently and in a well-balanced manner in a short time. The processed propolis is preferably a propolis ethanol extract.
[0026] The propolis extract includes the recovered extract (including further purified as necessary), the concentrated extract, and the solid obtained by removing the solvent from the extract by freeze-drying, spray-drying, etc. Here, the concentration, freeze-drying, and spray-drying of the extract can be carried out according to a conventional method. The propolis extract of the present invention also includes the powder obtained by powdering such an extract, and the granular form obtained by granulating the powder.
[0027] The content of propolis in the angiotensin II type 1 receptor inhibitor of the present invention is not particularly limited as long as it is within a range in which the effects of the present invention can be obtained, and can be appropriately adjusted depending on the final form, etc., and can be, for example, 0.00001 mass% or more, 0.0001 mass% or more, 0.001 mass% or more, 0.01 mass% or more, 0.1 mass% or more, 0.5 mass% or more, 1 mass% or more, 3 mass% or more, 5 mass% or more, 7 mass% or more, 10 mass% or more, 15 mass% or more, or more, based on the total solid content in the angiotensin II type 1 receptor inhibitor. % or more, 20 mass% or more, 30 mass% or more, 40 mass% or more, 50 mass% or more, 60 mass% or more, 70 mass% or more, 80 mass% or more, or 90 mass% or more, and 100 mass% or less, 90 mass% or less, 80 mass% or less, 70 mass% or less, It may be 60% by mass or less, 55% by mass or less, 50% by mass or less, 40% by mass or less, 30% by mass or less, 20% by mass or less, 15% by mass or less, 10% by mass or less, 7% by mass or less, 5% by mass or less, 3% by mass or less, 1% by mass or less, or 0.5% by mass or less.
[0028] The angiotensin II type 1 receptor inhibitor of the present invention can also be administered to humans to inhibit the binding of angiotensin II to angiotensin II type 1 receptor. The angiotensin II type 1 receptor inhibitor of the present invention can be administered orally or parenterally. Oral administration includes enteral administration, and parenteral administration includes topical administration, particularly transdermal administration.
[0029] In addition, the dosage of the angiotensin II type 1 receptor inhibitor of the present invention when administered orally may vary depending on the form of the active ingredient, the composition, and the application method and application amount, but for example, when the active ingredient is propolis, it can be used at a dose of 1 μg to 1,000 mg, preferably 3 μg to 500 mg, more preferably 5 μg to 250 mg, and even more preferably 7 μg to 100 mg, per day for an adult weighing 60 kg. The dosage can be appropriately increased or decreased depending on factors such as the health condition of the person taking it, the administration method, the type of active ingredient, and the combination with other agents.
[0030] The angiotensin II type 1 receptor inhibitor of the present invention may be administered once a day, or may be administered in multiple doses, such as twice a day, three times a day, etc., as long as the effective daily dose is within the above-mentioned range. The angiotensin II type 1 receptor inhibitor of the present invention is effective immediately after administration, but continuous administration for 1 to 4 weeks, or for one month or more, six months or more, or one year or more is preferable because the effect can be sustained longer.
[0031] The angiotensin II type 1 receptor inhibitor of the present invention can be used as food and drink (particularly food and drink intended for health, health maintenance, or promotion, etc. (e.g., health food, functional food, nutritional composition, dietary supplement, supplement, health food, food for specified health use, nutrient functional food, or food with functional labeling)), quasi-drug, pharmaceutical, etc. The angiotensin II type 1 receptor inhibitor of the present invention also encompasses the meaning of an additive that imparts angiotensin II type 1 receptor inhibitory action.
[0032] The propolis may be used as is in the above-mentioned foods and beverages, or may be mixed with minerals, vitamins, flavonoids, quinones, polyphenols, amino acids, nucleic acids, essential fatty acids, cooling agents, binders, sweeteners, disintegrants, lubricants, colorants, fragrances, stabilizers, gelling agents, preservatives, sustained-release regulators, surfactants, solubilizers, humectants, etc., as necessary.
[0033] Food and drink includes all foods and drinks that animals (including humans) can consume. The types of food and drink are not particularly limited, and examples thereof include dairy products, fermented foods (yogurt, etc.), beverages (soft drinks such as coffee, juice, and tea drinks, milk drinks, lactic acid bacteria drinks, drinks containing lactic acid bacteria, yogurt drinks, carbonated drinks, sake, Western liquor, and alcohol such as fruit wine, etc.), spreads (custard cream, etc.), pastes (fruit paste, etc.), Western confectionery (chocolate, donuts, pies, cream puffs, gum, gummies, jellies, candies, cookies, cakes, puddings, etc.), Japanese confectionery (daifuku, mochi, manju, castella, anmitsu, yokan, etc.), frozen desserts (ice cream, popsicles, sorbets, etc.), foods (curry, beef bowl, porridge, miso soup, soup, meat sauce, pasta, pickles, jam, etc.), and seasonings (dressing, furikake, umami seasoning, soup base, etc.).
[0034] The method for producing the food or drink is not particularly limited, and any known method can be used as appropriate.
[0035] The dosage unit form when used as a supplement is not particularly limited and can be selected as appropriate. Examples include tablets such as chewable tablets and lozenges, capsules, granules, liquids, powders, syrups, pastes, drinks, gummies, and the like.
[0036] The above-mentioned propolis can be used alone in the above-mentioned medicines, or can be mixed with other medicinal ingredients such as vitamins and herbal medicines listed in the Japanese Pharmacopoeia.
[0037] When the angiotensin II type 1 receptor inhibitor of the present invention is prepared as a pharmaceutical product, the propolis can be prepared together with pharmaceutical acceptable ingredients into the form of tablets (including plain tablets, sugar-coated tablets, effervescent tablets, film-coated tablets, chewable tablets, troches, etc.), capsules, pills, powders (dispersed medicines), fine granules, granules, liquids, suspensions, emulsions, syrups, pastes, injections (including the case where the propolis is mixed with distilled water or infusions such as amino acid infusions or electrolyte infusions at the time of use to prepare a liquid product), etc., to form a pharmaceutical preparation.
[0038] The pharmaceutical agent may be administered locally or systemically. There is no particular limitation on the administration method, and the pharmaceutical agent may be administered orally or parenterally. Parenteral administration routes include subcutaneous, intradermal, intramuscular, intraperitoneal, intravenous or intraarterial administration, and transdermal administration.
[0039] In addition to propolis, the pharmaceutical of the present invention may contain, as necessary, pharma- ceutically acceptable ingredients such as excipients, binders, disintegrants, lubricants, colorants, suspending agents, thickeners, antioxidants, absorption enhancers, pH adjusters, preservatives, stabilizers, surfactants, sweeteners, flavorings, and fragrances.
[0040] The pharmaceutical product of the present invention also includes quasi-drugs.
[0041] The angiotensin II type 1 receptor inhibitor of the present invention described above is applicable to mammals including humans (preferably humans).
[0042] The propolis produced in Hawaii, USA, and Taiwan, or propolis derived from a plant of the genus Macaranga, which the angiotensin II type 1 receptor inhibitor of the present invention contains as an active ingredient, has angiotensin II type 1 receptor inhibitory activity as shown in the examples described below, and is therefore useful as an active ingredient of angiotensin II type 1 receptor inhibitors. Since propolis produced in Hawaii, USA, and Taiwan, or propolis derived from a plant of the genus Macaranga have the effect of lowering blood pressure by inhibiting the binding of angiotensin II to the angiotensin II type 1 receptor, they can also be used as an active ingredient of a blood pressure lowering agent and a preventive and / or ameliorating agent for hypertension. The blood pressure lowering agent of the present invention may be one that has not only a blood pressure lowering effect but also a blood pressure rise suppressing effect. The angiotensin II type 1 receptor inhibitor of the present invention is also expected to have an anti-arteriosclerotic effect. The above description of the angiotensin II type 1 receptor inhibitor can be applied to the blood pressure lowering agent and the preventive and / or ameliorating agent for hypertension. That is, the content and dosage of propolis in the antihypertensive agent and the agent for preventing and / or ameliorating hypertension of the present invention are the same as those described above.
[0043] The antihypertensive agent and agent for preventing and / or improving hypertension of the present invention can be used as food and drink (particularly food and drink intended for health, maintaining or improving health, etc. (for example, health foods, functional foods, nutritional compositions, dietary supplements, supplements, health foods, foods for specified health uses, foods with nutrient functions, or foods with functional claims)), quasi-drugs, medicines, etc. The antihypertensive agent and agent for preventing and / or improving hypertension of the present invention also encompasses the meaning of additives that impart a blood pressure lowering effect and an effect of preventing and / or improving hypertension. The food and drink, quasi-drugs, and medicines are the same as those described above.
[0044] Furthermore, the angiotensin II type 1 receptor inhibitor, antihypertensive agent, and agent for preventing and / or ameliorating hypertension of the present invention use propolis, which has traditionally been used as a food ingredient, and therefore are highly safe. EXAMPLES
[0045] The present invention will be described in more detail below with reference to examples, although the present invention is not limited to the following examples.
[0046] Example 1 (Preparation of propolis extract) The propolis raw mass was pulverized, and 80% by volume ethanol was added and stirred at room temperature for 24 hours to extract. The extract was filtered through filter paper (No. 2, manufactured by Advantec Toyo Co., Ltd.) and then concentrated under reduced pressure using an evaporator. The concentrated liquid was freeze-dried to obtain a propolis extract.
[0047] Test Example 1 (Method for measuring angiotensin II AT1 inhibitory activity) Human recombinant AT1 expressed in CHO-K1 cells was used in Tris-HCl buffer (Tris Hydrochloride Acid Buffer) at pH 7.4. 10.3 μg of human recombinant AT1 was incubated with 0.02 nM [125I](Sar1,Ile8)-Angiotensin II and propolis extracts (derived from Macaranga genus plants) from Hawaii, USA and Taiwan at 37°C for 180 minutes. After filtering and washing the membranes, the amount of [125I](Sar1,Ile8)-angiotensin II that specifically bound was counted. The amount of [125I](Sar1,Ile8)-angiotensin II bound with and without the addition of propolis extract was compared, and the inhibition rate was calculated. The angiotensin II AT1 inhibition rates of the propolis from each production area obtained are shown in Table 1.
[0048] [Table 1]
[0049] Propolis produced in Hawaii, USA and Taiwan, unlike the Brazilian propolis disclosed in JP 2004-161664 A, are derived from plants of the Macaranga genus and have superior angiotensin II A T1 inhibitory activity, as confirmed in Table 1.
Claims
1. An angiotensin II type 1 receptor inhibitor comprising propolis produced in Hawaii, USA and / or propolis produced in Taiwan.
2. An angiotensin II type 1 receptor inhibitor comprising propolis derived from plants of the Macaranga genus.
3. An antihypertensive agent comprising the angiotensin II type 1 receptor inhibitor according to claim 1.
4. An antihypertensive agent comprising the angiotensin II type 1 receptor inhibitor according to claim 2.
5. 2. An agent for preventing and / or ameliorating hypertension, comprising the angiotensin II type 1 receptor inhibitor according to claim 1.
6. A preventive and / or ameliorating agent for hypertension, comprising the angiotensin II type 1 receptor inhibitor according to claim 2.
7. The agent according to any one of claims 1 to 6, which is a food or drink, a medicine, or a quasi-drug.
Citation Information
Patent Citations
Propolis composition
JP2004161664A
P21-activating kinase inhibitors
JP2018002678A
